Latest post on other site to try and sway new eyes
Post# of 72447
(Total Views: 463)
Posted On: 05/22/2019 9:23:33 AM
Latest post on other site to try and sway new eyes to investing in IPIX:
One of the primary criteria in investing is to find a company that is targeting an acceptable level of revenue for their products. Let's look at the markets that IPIX products are attacking and see how it compares to other companies, many of these on the NYSE and some even on the DOW":
Kevetrin: Cancer $90 B/yr
Brilacidin OM 2 B/yr
IBD 35 B/yr
Dermatology 40 B/yr
Unknown 30 B/yr (Dr B has said possible applications hardly scratched yet so $30 B should be an extremely conservative number)
Total nearly $200 Billion / yr
Will IPIX get the whole ball of wax noted above? Of course not. But all it needs is 2% to receive $4 Billion / yr.
Now look at the science of Brilacidin and Kevetrin, do they appear to have the ability to achieve a 2% penetration of the total markets they are addressing? I would venture to say they have a more than good chance to achieve this.
So how many other investments could one find today that give these types of returns on an investment that costs basically a quarter a share?
As I have been saying, certainly makes IPIX a strong candidate for funds an investor has set aside for high-risk investment. And now with multiple indications and clinical trials that have progressed past the most severe areas of inspection where most fail, the risk has been severely reduced. Not to mention the near term expectations for signing partnerships with global pharmas as evidenced by company PRs over the last month.
Risk? Yes But all you are putting up is a quarter a share.
Certainly something to think about.
One of the primary criteria in investing is to find a company that is targeting an acceptable level of revenue for their products. Let's look at the markets that IPIX products are attacking and see how it compares to other companies, many of these on the NYSE and some even on the DOW":
Kevetrin: Cancer $90 B/yr
Brilacidin OM 2 B/yr
IBD 35 B/yr
Dermatology 40 B/yr
Unknown 30 B/yr (Dr B has said possible applications hardly scratched yet so $30 B should be an extremely conservative number)
Total nearly $200 Billion / yr
Will IPIX get the whole ball of wax noted above? Of course not. But all it needs is 2% to receive $4 Billion / yr.
Now look at the science of Brilacidin and Kevetrin, do they appear to have the ability to achieve a 2% penetration of the total markets they are addressing? I would venture to say they have a more than good chance to achieve this.
So how many other investments could one find today that give these types of returns on an investment that costs basically a quarter a share?
As I have been saying, certainly makes IPIX a strong candidate for funds an investor has set aside for high-risk investment. And now with multiple indications and clinical trials that have progressed past the most severe areas of inspection where most fail, the risk has been severely reduced. Not to mention the near term expectations for signing partnerships with global pharmas as evidenced by company PRs over the last month.
Risk? Yes But all you are putting up is a quarter a share.
Certainly something to think about.
(6)
(0)